Cabot Wealth Management Inc. Sells 170 Shares of Insulet Co. (NASDAQ:PODD)

Cabot Wealth Management Inc. decreased its position in shares of Insulet Co. (NASDAQ:PODD) by 1.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,813 shares of the medical instruments supplier’s stock after selling 170 shares during the quarter. Cabot Wealth Management Inc.’s holdings in Insulet were worth $4,128,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Baillie Gifford & Co. boosted its position in Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after acquiring an additional 79,982 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Insulet by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after buying an additional 22,850 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after buying an additional 163,388 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PODD. JPMorgan Chase & Co. boosted their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Piper Sandler lifted their price target on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup boosted their price objective on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday. TD Cowen raised their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Finally, Stifel Nicolaus boosted their price objective on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $289.06.

Insulet Trading Down 1.9 %

Shares of PODD stock opened at $282.80 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock’s 50 day simple moving average is $272.98 and its two-hundred day simple moving average is $247.46. The company has a market cap of $19.84 billion, a PE ratio of 48.84, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Research analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.